Aplastic Anemia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Aplastic Anemia – Drugs In Development, 2024 report and make more profitable business decisions.
Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness, and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders, and serious infections. Treatment includes immunosuppressants and stem cell transplant.
The Aplastic Anemia drugs in development market research report provide comprehensive information on the therapeutics under development for Aplastic Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Aplastic Anemia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 16 molecules, with 14 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Aplastic Anemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Aplastic Anemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Aplastic Anemia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ASC Therapeutics IncBellicum Pharmaceuticals Inc
Case Western Reserve University
Cell Source Inc
Cellenkos Inc
F. Hoffmann-La Roche Ltd
Gamida Cell Ltd
Hangzhou Zede Pharmaceutical Technology Co Ltd
HemoGenyx Pharmaceuticals Plc
King's College Hospital NHS Foundation Trust
Kyowa Kirin Co Ltd
Novartis AG
Ono Pharmaceutical Co Ltd
Regen BioPharma Inc
Regeneron Pharmaceuticals Inc
SAB Biotherapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Aplastic Anemia reports